Bavarian Nordic A/S announced that the Public Health Agency of Canada (PHAC) will be purchasing Imvamune smallpox vaccine at a value of approximately US$ 56 million. The non-replicating smallpox vaccine is also approved for use against monkeypox in Canada as the only territory other than the USA.
Deliveries of vaccines under this five-year contract are expected to occur from 2023. Hence this contract will have no impact on the company
